Our 2026 global market reports are now updated with the latest data, delivering insights into key trends, segments, and growth drivers.
The Pergoveris market is evolving rapidly, driven by advancements in fertility treatments and a growing awareness of reproductive health issues worldwide. As more individuals seek solutions for infertility, the demand for effective hormone therapies like Pergoveris is on the rise.
Let’s explore the market’s current size, key drivers, segmentation, emerging trends, regional dynamics, and leading players shaping this sector.
Market Expansion and Forecast for the Pergoveris Market
During the historical period, the Pergoveris market witnessed growth due to several factors, including better diagnosis of gonadotropin deficiencies, the expansion of assisted reproductive clinics, improved IVF success rates, widespread availability of recombinant hormone technologies, and increasing awareness of infertility issues. Moving into the forecast period, the market is expected to benefit from growing demand for advanced IVF protocols, a stronger focus on precision hormone therapies, the rise of fertility tourism, greater use of patient-friendly injectable formats, and increased investments in reproductive biotechnology.
Key trends anticipated in the coming years involve wider adoption of recombinant hormone treatments, rising demand for IVF and assisted reproductive technology (ART) procedures, increased use of injectable pen devices, expansion of precision-controlled fertility therapies, and enhanced efforts to manage hormone deficiencies more effectively.
Download the Free Report Sample Now:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
Primary Factors Fueling Growth in the Pergoveris Market
One of the major contributors to the Pergoveris market’s expansion is the rising prevalence of infertility. This condition, characterized by difficulty in conceiving or carrying a pregnancy to term, is becoming more common due to delayed childbearing, lifestyle factors, environmental toxins, and health issues such as polycystic ovary syndrome (PCOS) and endometriosis.
Pergoveris plays a vital role in treating infertility by combining follicle-stimulating hormone (FSH) and luteinizing hormone (LH) to stimulate ovarian function, especially in women with severe gonadotropin deficiencies. For example, in April 2023, the World Health Organization reported that approximately 17.5% of the global adult population, or roughly one in six people, experience infertility.
This growing prevalence is a significant driver behind the increasing use of Pergoveris.
Increasing Use of IVF Procedures Strengthens Pergoveris Market Demand
Another key driver for the Pergoveris market is the widespread adoption of in vitro fertilization (IVF) procedures. IVF involves fertilizing an egg with sperm outside the body and then implanting the embryo in the uterus, helping individuals or couples overcome fertility challenges.
The rise in IVF procedures is linked to factors such as postponing parenthood for career or education, which leads to age-related fertility issues and a greater need for fertility treatments. Pergoveris supports IVF patients by promoting controlled ovarian stimulation and improving pregnancy outcomes, particularly for those with a low ovarian response.
For instance, in June 2025, the Human Fertilisation & Embryology Authority in the UK reported that in 2023, over 52,400 patients underwent more than 77,500 IVF cycles at licensed clinics. Additionally, egg freezing cycles rose from 4,700 in 2022 to 6,900 in 2023, representing 7% of all treatments.
These trends highlight how the growing use of IVF is boosting demand for Pergoveris.
Download the Detailed Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
Key Segmentation Categories in the Pergoveris Market
The Pergoveris market is organized into several important segments to better understand its composition. These include:
1) Formulation – covering Injectable Pen and Vial formulations
2) Indication – divided into Anovulation and Assisted Reproductive Technology (ART) procedures
3) Distribution Channel – including Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies
4) End Use – broken down into Hospitals, Clinics, Ambulatory Care, and Home Care settings
This segmentation helps clarify how the product is delivered and used across different patient needs and healthcare environments.
Innovation and Regulatory Advances Shaping the Pergoveris Market
Leading companies in the Pergoveris space are focusing on regulatory innovations and access improvements to accelerate treatment availability and affordability. One notable trend is the use of priority-review filings under the FDA Commissioner’s National Priority Voucher (CNPV) program, which shortens the approval period from the usual 10-12 months down to 1-2 months.
This expedites patient access to new reproductive therapies without compromising safety or efficacy. For example, in October 2025, EMD Serono, part of Merck KGaA, filed Pergoveris under the FDA CNPV program.
Pergoveris combines recombinant human FSH and LH in a 2:1 ratio and is delivered through a pre-filled Redi-ject pen, which simplifies dosing, reduces the number of injections, and improves the patient experience. Designed to mimic natural reproductive hormones, this therapy supports follicle development in assisted reproductive cycles.
The initiative aligns with public-private partnerships and direct-to-consumer access programs that aim to make such treatments more affordable and accessible for women with severe FSH/LH deficiencies.
Regional Insights Highlighting Market Performance in Pergoveris
As of 2025, Europe holds the largest share of the Pergoveris market. However, the Asia-Pacific region is forecasted to experience the fastest growth during the upcoming years.
The market report analyzes major regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, presenting a comprehensive global outlook on how the Pergoveris market is developing worldwide.
Leading Companies Driving Progress in the Pergoveris Market
Merck KGaA stands out as a prominent player actively shaping trends and innovations within the Pergoveris market. Their focus on regulatory advancements, patient-centric delivery systems, and strategic filings under priority review programs is helping to expand access and improve treatment outcomes for infertility patients globally.
Access This Detailed Market Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=20181
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
